So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.
Biological: lanadelumab
single dose, or two doses administered iv
Other: regular care
no lanadelumab administration, treated according to regular care
Inclusion Criteria:
- Patient is SARS-COV2 positive (PCR)
- Without oxygen a saturation below 90%
- At least 3L/min oxygen dependent
- Patient is 16 years and older
Exclusion Criteria:
- Has previously participated in this study
- Acute myocardial or cerebral ischemic event at time of enrolment
- Receiving ACE or ARB inhibitor or comparable drugs that is specified as an
intervention in this domain as a usual medication prior to this hospitalization will
exclude a patient from receiving that agent
- A baseline alanine aminotransferase or an aspartate aminotransferase that is more than
five times the upper limit of normal
- Patient is known hypersensitive to full human monoclonal antibodies
- Patient is pregnant or breast feeding
Amsterdam UMC
Amsterdam, Netherlands
Rijnstate hospital
Arnhem, Netherlands
Radboudumc
Nijmegen, Netherlands
UMC Utrecht
Utrecht, Netherlands